Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 5.30%, which has investors questioning if this is right time to buy.

Inhibikase Therapeutics' chief financial officer, Garth Lees-Rolfe, has resigned from the clinical-stage pharmaceutical company, which has hired David McIntyre as its new finance chief.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...

Inhibikase Therapeutics (IKT) announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025.Stay Ahead of ...

Vancouver, April 14, 2025 (GLOBE NEWSWIRE) -- To help address the need for a significant increase in housing, the BC Real ...

Every investor in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) should be aware of the most powerful shareholder groups. We can see that hedge funds own the lion's share in the company with 31% ...

Every investor in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) should be aware of the most powerful shareholder groups. We can see that hedge funds own the lion's share in the company with 31% ownership ...

On Monday, H.C. Wainwright reaffirmed a Neutral rating on shares of Inhibikase Therapeutics Inc (NASDAQ:IKT), which currently trades at $2.29 and has seen a significant 76% surge over the past six ...